U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07776522) titled 'Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration' on Aug. 12.
Brief Summary: This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Intervention:
DRUG: JWK001
JWK001 will be administered as a single subretinal injection in one study eye.
DRUG: Aflibercept (2.0 mg)
...